BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiang X, Yuan D, Liu Y, Li J, Wen Q, Kong P, Gao L, Zhang C, Gao L, Peng X, Zhang X. PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression. Acta Biochim Biophys Sin (Shanghai) 2018;50:800-6. [PMID: 30020405 DOI: 10.1093/abbs/gmy076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lee B, Lee H, Cho J, Yoon SE, Kim SJ, Park WY, Kim WS, Ko YH. Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:628807. [PMID: 33777778 DOI: 10.3389/fonc.2021.628807] [Reference Citation Analysis]
2 Pinelli S, Alinovi R, Poli D, Corradi M, Pelosi G, Tiseo M, Goldoni M, Cavallo D, Mozzoni P. Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1. Int J Mol Med 2021;47:117. [PMID: 33955505 DOI: 10.3892/ijmm.2021.4950] [Reference Citation Analysis]
3 Li J, Zhou W, Mao Q, Gao D, Xiong L, Hu X, Zheng Y, Xu X. HMGB1 Promotes Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cells by Inducing Autophagy via the AMPK/mTOR Signaling Pathway. Front Oncol 2021;11:739145. [PMID: 34778055 DOI: 10.3389/fonc.2021.739145] [Reference Citation Analysis]
4 Komar D, Juszczynski P. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. Clin Epigenetics 2020;12:147. [PMID: 33054831 DOI: 10.1186/s13148-020-00941-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Li B, Wan Q, Li Z, Chng WJ. Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. Cancers (Basel) 2021;13:5147. [PMID: 34680295 DOI: 10.3390/cancers13205147] [Reference Citation Analysis]
6 Ahmadpour S, Taghavi T, Sheida A, Tamehri Zadeh SS, Hamblin MR, Mirzaei H. Effects of microRNAs and long non-coding RNAs on chemotherapy response in glioma. Epigenomics 2022. [PMID: 35473299 DOI: 10.2217/epi-2021-0439] [Reference Citation Analysis]
7 Trigg RM, Lee LC, Prokoph N, Jahangiri L, Reynolds CP, Amos Burke GA, Probst NA, Han M, Matthews JD, Lim HK, Manners E, Martinez S, Pastor J, Blanco-Aparicio C, Merkel O, de Los Fayos Alonso IG, Kodajova P, Tangermann S, Högler S, Luo J, Kenner L, Turner SD. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Nat Commun 2019;10:5428. [PMID: 31780656 DOI: 10.1038/s41467-019-13315-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Wang W, Han S, Gao W, Feng Y, Li K, Wu D. Long Noncoding RNA KCNQ1OT1 Confers Gliomas Resistance to Temozolomide and Enhances Cell Growth by Retrieving PIM1 From miR-761. Cell Mol Neurobiol 2020. [PMID: 32897512 DOI: 10.1007/s10571-020-00958-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]